Maze Therapeutics, Inc. (MAZE)

NASDAQ • Healthcare

$31.01

-$0.93 (-2.9%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$31.86

Previous Close$31.01

Day Range$30.54 - $31.86

Avg. Volume (3M)854K

Market Cap$1.7B

52 Week Range

$21.95$53.65

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$20M

Net Income (TTM)

-$133.5M

EPS (TTM)

-$2.74

ROA (TTM)

-25.13%

Current Ratio

18.31

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+2.5%Q3 2025-$0.77

+10.8%Q4 2025-$0.66

+11.0%Q1 2026-$0.65

-4.7%Q2 2026-$0.45

-6.0%Q3 2026-$0.76

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -6.0%

Maze Therapeutics’ loss per share trailed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 12, 2026, with EPS of -$0.76 trailing the -$0.72 estimate (difference -$0.04) as the early-stage biotech continued investing in its genetic-medicine pipeline across kidney and metabolic disease programs. The company posted GAAP net income of roughly -$44.7 million, a -32.8% year-over-year change from about -$33.7 million a year ago, alongside GAAP operating income of around -$48.0 million. Cash use also remained elevated, with negative operating cash flow of about -$15.1 million during the quarter. For the next period, consensus calls for EPS of -$0.79 on revenue of $333,333.00.

Next report — what to expect

Maze Therapeutics, Inc. (MAZE) reports next on November 5, 2026. Wall Street is expecting EPS of -$0.76 on revenue of $333,333.00. Traders will be watching how results compare with those consensus figures; MAZE has beaten EPS in 3 of its 7 most recent quarters.

View full earnings history

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing genetic-medicine candidates in the United States. In qualitative terms it is an early-stage drug developer rather than a commercial biopharma company. The pipeline centers on kidney and metabolic diseases, and the company came public in 2025.

Name

Maze Therapeutics, Inc.

CEO

Jason Coloma

Website

www.mazetx.com

Industry

Healthcare

Year Founded

2017

Employees

141

Today's Snapshot

AI-generated

MAZE closed 2.9% below yesterday's close, in line with a weaker sector. Shares changed hands at about half of its usual level. MAZE is due to report earnings on 5 November.

Trading Volume

Below 10d avg (970.0K)

505.2K

vs S&P 500 Today

Underperforming Market

-2.42%

Updated: October 23, 2026 at 20:09 UTC

Technical Indicators

5 Buy1 Neutral2 Sell

MAZE shows clear short- and intermediate-term strength that supports the buy rating, with momentum measures and MACD in bullish territory and price trading above most short- and mid-term averages. However, the stock remains slightly below the 200-day level and volatility is elevated, and the classic pivot sits above the market, so broader trend confirmation is incomplete. OBV signals constructive volume, which reinforces near-term strength while the 200-day resistance and wider ATR temper the case. Technical takeaway: Buy — short/medium momentum and volume are constructive despite 200-day resistance.

All signals

EMA (5 indicators)$27.66 - $31.54
Buy
RSI (14)63.31
Neutral
Stochastic %K (14, 3, 3)83.50
Sell
MACD Level (12, 26)1.33
Buy

Peers & Related Assets

PTCTPTC Therapeutics, Inc.

$60.59-3.9%

TVTXTravere Therapeutics, Inc.

DMACDiaMedica Therapeutics Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.